Evotec SE is to conduct small molecule drug development across multiple therapeutic areas for Takeda Pharmaceutical Company Ltd under a new multi-year collaboration designed to deliver clinical drug candidates. The upfront fee hasn’t been disclosed, but preclinical, clinical and commercial milestones could amount to more than $170 million per programme. The agreement covers at least five drug discovery programmes.
